培养阴性医院获得性肺炎中降阶梯治疗MRSA的结局
这项单中心回顾性队列研究纳入2012至2017年成人医院获得性肺炎且呼吸道培养阴性的患者279例,降阶梯组92例(启动抗MRSA药物4天内停用),未降阶梯组187例。未降阶梯组抗MRSA覆盖时间多5天,但28天死亡率无差异(未降阶梯组28% vs 降阶梯组23%;差值-5.5%;95%CI -16.1至6.5)。降阶梯组住院时间更短(15天 vs 20天;差值3.2天;95%CI 0.1-6.4),急性肾损伤发生率更低(36% vs 50%;差值-13.8%;95%CI -26.9至-0.4)。
要点
- 培养阴性医院获得性肺炎中,启动抗MRSA药物4天内停用(降阶梯)与28天死亡率无差异:未降阶梯组28% vs 降阶梯组23%,差值-5.5%(95%CI -16.1至6.5)。
- 降阶梯组住院时间较未降阶梯组缩短:15天 vs 20天,差值3.2天(95%CI 0.1-6.4)。
- 降阶梯组急性肾损伤发生率低于未降阶梯组:36% vs 50%,差值-13.8%(95%CI -26.9至-0.4)。
- 未降阶梯组抗MRSA覆盖时间比降阶梯组多5天。
- 降阶梯组ICU住院时间较未降阶梯组缩短:10天 vs 13天,差值2.2天(95%CI -0.3至4.9)。
适用人群与场景
- 成人医院获得性肺炎且呼吸道培养阴性的患者,2012至2017年入院。
诊断标准与关键阈值
- 降阶梯定义为启动抗MRSA药物后4天内停用。
研究设计与关键结果
- 单中心回顾性队列研究,纳入279例成人医院获得性肺炎且呼吸道培养阴性的患者,降阶梯组92例,未降阶梯组187例。
- 未降阶梯组抗MRSA覆盖时间比降阶梯组多5天。
- 28天死亡率:未降阶梯组28% vs 降阶梯组23%,差值-5.5%(95%CI -16.1至6.5)。
- 住院时间:降阶梯组15天 vs 未降阶梯组20天,差值3.2天(95%CI 0.1-6.4)。
- ICU住院时间:降阶梯组10天 vs 未降阶梯组13天,差值2.2天(95%CI -0.3至4.9)。
- 急性肾损伤发生率:降阶梯组36% vs 未降阶梯组50%,差值-13.8%(95%CI -26.9至-0.4)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在培养阴性的医院获得性肺炎中,启动抗MRSA药物后4天内停用降阶梯治疗未影响28天死亡率,且与更短住院时间和更低急性肾损伤发生率相关;作者认为该策略可能安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In culture-positive nosocomial pneumonia, de-escalation (DE) from broad-spectrum empirical antimicrobials to narrower-spectrum agents has shown to decrease broad-spectrum antibiotic use without compromising patient outcomes. However, uncertainty exists regarding the safety of anti-methicillin-resistant Staphylococcus aureus (MRSA) agent DE in culture-negative nosocomial pneumonia. This study aimed to determine if anti-MRSA agent DE in culture-negative nosocomial pneumonia affects 28-day and hospital mortality, ICU and hospital length of stay (LOS), treatment failure, and safety.
METHODS: This single-center retrospective cohort study included adult patients admitted from 2012 to 2017 with nosocomial pneumonia and a negative respiratory culture. DE was defined as anti-MRSA agent discontinuation within 4 days of initiation. Secondary outcomes included hospital mortality, hospital and ICU LOS, treatment failure, and occurrence of acute kidney injury (AKI).
RESULTS: Of 279 patients included, 92 were in the DE group and 187 were in the no DE (NDE) group. Patients who were not de-escalated received 5 more days of MRSA coverage than patients who were de-escalated; however, there was no difference in 28-day mortality (NDE group, 28% vs DE group, 23%; difference, -5.5%; 95% CI, -16.1 to 6.5). Patients who were de-escalated had shorter hospital (DE group, 15 days vs NDE group, 20 days; difference, 3.2 days; 95% CI, 0.1-6.4) and ICU (DE group, 10 days vs NDE group, 13 days; difference, 2.2 days; 95% CI, -0.3 to 4.9) LOSs after the index date. The incidence of AKI was significantly higher in patients who were not de-escalated (DE group, 36% vs NDE group, 50%; difference, -13.8%; 95% CI, -26.9 to -0.4).
CONCLUSIONS: Although anti-MRSA agent DE in culture-negative nosocomial pneumonia did not affect 28-day mortality, it was associated with a shorter hospital LOS and lower incidence of AKI.
参考来源
- Cowley MC, Ritchie DJ, Hampton N, et al. Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia. Chest. 2018. PMID: 30621854. doi:10.1016/j.chest.2018.10.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。